Application of an intragenic genomic probe to genetic counselling for haemophilia B in the west of Scotland

J M Connor*, A F Pettingrew†, I M Hannon†, C D Forbes†, G D O Lowe†, and N A Affara*

From *the Department of Medical Genetics and †the Department of Haematology, University of Glasgow, Glasgow.

SUMMARY Total ascertainment revealed 28 families with haemophilia B in the west of Scotland (prevalence 1/26 870 males). In 12 of these families more than one person was affected and 26 living obligate carriers were identified and tested. Of these, 42% were heterozygous for a DNA polymorphism recognised by a factor IX genomic probe. No recombination was observed in 11 phase known and four phase unknown informative meioses. Definitive genetic counselling was possible for 14 of 42 females at risk, 11 could not be traced, in 10 the probe was not informative, and in seven paternal absence prevented interpretation. Linkage disequilibrium was apparent for this restriction fragment length polymorphism and haemophilia B in the west of Scotland.

The principal difficulties in genetic counselling of families with haemophilia B (Christmas disease, factor IX deficiency) relate to detection of female carriers and early prenatal diagnosis of affected males. Levels of factor IX coagulant activity (IX:C) have a wide normal range (60 to 160%) and serial assays in a single person can vary considerably.1 Measurement of factor IX coagulant activity alone can confidently identify fewer than 50% of obligate carriers.2 Simultaneous immunoradiometric assay of the level of factor IX antigen (IX:Ag) improves detection of obligate carriers to 90% in the less common CRM positive variants of haemophilia B, but only increases the detection level to 56% in the CRM negative variants.3 The carrier likelihood from these assays can be combined with pedigree information using Bayes’s theorem.4 Prenatal diagnosis is possible after fetal blood sampling in male pregnancies but has the disadvantages of a significant fetal mortality and, if positive, a late termination of pregnancy.5 6

A recombinant DNA approach to these difficulties became possible with the isolation of the human factor IX gene and the characterisation of a frequent intragenic polymorphic marker.7–9 We report our experience in the west of Scotland using this probe for genetic counselling of families with haemophilia B.

Subjects and methods

Patients with haemophilia B were identified from the records of the Regional Haemophilia Reference Centre at the Glasgow Royal Infirmary and the Royal Hospital for Sick Children, Glasgow, and from the genetic register of the West of Scotland Regional Genetics Service. An extended pedigree was obtained and blood samples were taken for DNA analysis and coagulation studies.

DNA was extracted using the method of Kunkel et al.10 The DNA fragments produced by digestion with the restriction enzyme TaqI were separated by electrophoresis in 0.8% agarose gel and transferred to nitrocellulose filters (Schleicher and Schüll) by Southern blotting.11 Probe VIII is a 2.5 kb segment of the factor IX gene comprising 2.4 kb of introns and the ‘d’ exon.12 This probe was labelled with 32P by nick translation.13 Hybridisation was carried out at 42°C in 50% formamide, 1 × Denhardt’s solution, 5 × SSC, 20 mmol/l NaH2PO4 (pH 6.8), 0.1 mg/ml heat denatured salmon sperm DNA, 20 g/ml poly A, and 10% dextran sulphate. After hybridisation, excess probe was removed by washing twice in 1 × SSC, 0.1% sodium dodecyl sulphate (SDS) at room temperature for 20 minutes, followed by one
or two washes in 0.1 × SSC, 0.1% SDS for 30 minutes at 63°C. DNA bands were detected by autoradiography with x-ray film and intensifying screens.

Results

Probe VIII identifies two bands in blots of DNA from males and two or three bands in blots of DNA from females (fig 1). The 5.3 kb band occurred in all subjects. In male subjects the second band was either 1.8 kb or 1.3 kb. The 500 bp fragment cleaved in the production of the 1.3 kb fragment is not visualised. Females were heterozygous (1.8/1.3 kb) or homozygous for either fragment. In the unrelated Scottish subjects (six males and 20 females) the frequency of the 1.8 kb fragment was 0.63 (29 of 46 X chromosomes) and of the 1.3 kb fragment 0.37 (17 of 46 X chromosomes).

Fifty-two males with haemophilia B were identified with an age range of 2 to 76 years. This represents a prevalence of 1 in 26 870 males.

Initially these were considered to belong to 35 separate families but extended pedigrees revealed that several were related. Of the remaining 28 families, 16 contained only a single affected male and 12 had two or more affected subjects. Three of these 12 families refused to cooperate but the pedigrees and results of the others are shown in figs 2 to 10.

FIG 1  X chromosomal restriction fragment length polymorphism revealed by hybridisation to probe VIII after TaqI digestion.

FIG 2–10 Pedigrees of familial cases of haemophilia B in the west of Scotland. Probe VIII/TaqI restriction fragment pattern (1.8 kb, 1.3 kb) is indicated for each subject as is the level of factor IX activity in certain subjects.

FIG 2  Pedigree 1756.

FIG 3  Pedigree 2377.

FIG 4  Pedigree 3569.
Application of an intragenic genomic probe to genetic counselling for haemophilia B in Scotland

These nine families contained 29 living obligate carriers and 26 of these were traced and tested. Eleven (42%) were heterozygous (1-8/1-3) for probe VIII and thus potentially informative; 14 were homozygous for the 1-3 kb fragment and one was homozygous for the 1-8 kb fragment. Levels of factor IX activity were measured in eight obligate carriers and only one had a value (58%) outside the normal range.
TABLE 1 DNA results for females at risk of haemophilia B.

<table>
<thead>
<tr>
<th>Family contemplated</th>
<th>Obligate carrier*</th>
<th>Not a carrier*</th>
<th>Not informative</th>
<th>Father not available</th>
<th>Not traced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family completed</td>
<td>4</td>
<td>7</td>
<td>7†</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>4</td>
<td>10</td>
<td>10</td>
<td>7</td>
<td>11</td>
</tr>
</tbody>
</table>

*Excluding intragenic recombination.
†In two cases the fathers were also unavailable.

TABLE 2 DNA results in familial cases of haemophilia B.

<table>
<thead>
<tr>
<th>Family</th>
<th>Average factor IX level in affected males (%)</th>
<th>RFLP fragment linked to the mutant factor IX (kb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4542</td>
<td>&lt;1</td>
<td>1-3</td>
</tr>
<tr>
<td>1756</td>
<td>6</td>
<td>1-3</td>
</tr>
<tr>
<td>4555</td>
<td>6</td>
<td>1-3</td>
</tr>
<tr>
<td>2377</td>
<td>8</td>
<td>1-3</td>
</tr>
<tr>
<td>3569</td>
<td>8</td>
<td>1-3</td>
</tr>
<tr>
<td>4549</td>
<td>22</td>
<td>1-3</td>
</tr>
<tr>
<td>4565</td>
<td>&lt;1</td>
<td>1-8</td>
</tr>
<tr>
<td>4559</td>
<td>3</td>
<td>1-8</td>
</tr>
<tr>
<td>4551</td>
<td>17</td>
<td>1-8</td>
</tr>
</tbody>
</table>

Forty-two females at risk were identified. Each had a pedigree risk of greater than or equal to 1 in 4. Thirty-one of these females were traced and tested and the results are summarised in table 1 and subdivided according to whether or not family extension was contemplated.

No recombination was observed in 11 phase known informative meioses and four phase unknown meioses.

In six of these nine families haemophilia B was segregating with the less frequent 1-3 kb restriction fragment (table 2). From the RFLP frequencies in the general population only three of these families would have been expected to have the mutant factor IX allele linked to the 1-3 kb restriction fragment. This difference is statistically significant ($\chi^2 = 4.5$, p<0.05).

Discussion

Haemophilia B shows marked genetic heterogeneity but in all of these variants the primary defect is a reduction in factor IX activity. Thus a polymorphic intragenic probe from the factor IX gene is the ideal marker for the mutant allele. Gianelli et al predicted such a marker (probe VIII) in three families segregating for haemophilia B and observed no recombination. However, these families only included three phase known informative meioses. In nine families from the west of Scotland no recombination was observed in 15 further opportunities for recombination.

Gianelli et al predicted that the polymorphism detected by probe VIII would be helpful in genetic counselling of about 40% of affected families on the basis of the expected heterozygote frequency. We found a similar frequency for this RFLP in the west of Scotland and the probe was informative for 42% (11 of 26) obligate carrier females (table 3). Although the heterozygote frequency was close to that predicted from the Hardy-Weinberg equilibrium, the homozygote frequencies for this RFLP were disturbed by linkage disequilibrium.

In our families, 14 of 31 (45%) females at high risk could be definitively counselled using this single polymorphic probe. Non-informative matings prevented counselling of 10 and paternal absence prevented counselling of seven females at risk. Both of these problems could be circumvented by applying other intragenic or closely linked RFLPs to produce a haplotype for the mutant allele.

There is increasing evidence for heterogeneity among families with haemophilia B. For example, Parekh et al in a multicentre study of 98 families found 52 to be CRM negative, 30 to be CRM reduced, and 16 to have CRM levels above or equal to those expected from their levels of factor IX coagulant activity. Gene deletions of variable size

TABLE 3 Frequencies of the restriction fragment length polymorphism detected by probe VIII after TaqI digestion.

<table>
<thead>
<tr>
<th>RFLP fragment frequencies</th>
<th>Number of X chromosomes analysed</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-8 kb</td>
<td>1-3 kb</td>
<td></td>
</tr>
<tr>
<td>0-65</td>
<td>0.35</td>
<td>45</td>
</tr>
<tr>
<td>0-65</td>
<td>0.365</td>
<td>63</td>
</tr>
<tr>
<td>0-63</td>
<td>0.37</td>
<td>46</td>
</tr>
</tbody>
</table>
have been demonstrated in five of the six known British haemophilia B patients who have factor IX antibodies.\textsuperscript{12,17} In patients without gene deletions the clinical and haematological evidence for heterogeneity would suggest a wide variety of molecular pathology, yet for all subjects the linked RFLP approach to carrier detection and prenatal diagnosis would be applicable.

Although prenatal diagnosis of haemophilia B has been possible after fetoscopic blood sampling since 1979, only about one third of females at risk use this procedure.\textsuperscript{18,19} However, in each of these studies most women had limited their families in view of the risk. First trimester prenatal diagnosis of haemophilia B is now feasible with sexing and DNA diagnosis on chorion biopsy material for phase known mothers, and it might be expected that the proportion of mothers at risk who use prenatal diagnosis will increase.

Edwards\textsuperscript{20} has estimated that a DNA segment 100 kb long has only a 50% chance of rearrangement in 700 generations or about 20 000 years. Hence, any haemophilia B family, even if extensive, will show non-random association or linkage disequilibrium for this intragenic RFLP and the disease mutation. However, linkage disequilibrium at a population level for haemophilia B and this intragenic RFLP would not be expected. Indeed, overall, the proportions of families with linkage to each RFLP fragment should reflect the individual fragment frequencies. In the west of Scotland there is a statistically significant departure from the expected ratio with most families demonstrating linkage to the less frequent 1-3 kb fragment. This is probably due to chance, but an alternative explanation might be that some of these families are distantly related, especially those with similar levels of factor IX activity (table 2). This would be supported by finding an identical haplotype for several intragenic RFLPs in related families. Linkage disequilibrium is of practical importance as it will either increase or decrease the predicted value of a linked marker according to whether the disease is linked to the less frequent or more frequent allele.\textsuperscript{21}

Thus a single polymorphic intragenic marker can help a substantial number of females at risk in families with haemophilia B. If technical problems such as confusion of samples and partial digestion are excluded then the only sources of error are intragenic recombination and disease due to a non-syntenic regulator mutation. The latter can be excluded by typing informative family members and the former is estimated to occur with a frequency of only 1 in 5000 to 10 000 for a recognition site 10 to 20 kb from the disease mutation.\textsuperscript{22} Linkage disequilibrium, non-information, and maternal absence are important limitations both for this and other similar studies, but despite these this study has demonstrated the practical value of this approach to genetic counselling for a single gene disorder.

We wish to thank Professor G G Brownlee for supplying probe VIII. This study was supported in part by grants from the Wellcome Trust and the National Fund for Research into Crippling Diseases.

References
\begin{enumerate}
\item Anson DS, Choo KH, Rees DJG, et al. The gene structure of human anti-haemophilic factor IX. EMBO J 1984;3:1053-60.
\item Evans DIK, Shaw A. Attitudes of haemophilia carriers to fetoscopy and amniocentesis. Lancet 1979;i:1371.
\end{enumerate}


Correspondence and requests for reprints to Dr J M Connor, Duncan Guthrie Institute of Medical Genetics, Yorkhill, Glasgow G3 8SJ.
Application of an intragenic genomic probe to genetic counselling for haemophilia B in the west of Scotland.

J M Connor, A F Pettigrew, I M Hann, C D Forbes, G D Lowe and N A Affara

*J Med Genet* 1985 22: 441-446
doi: 10.1136/jmg.22.6.441

Updated information and services can be found at:
http://jmg.bmj.com/content/22/6/441

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/